




Searching News Database: Biovitrum
HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
HSMN NewsFeed - 15 Oct 2021
Aspaveli(R) (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
Aspaveli(R) (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
HSMN NewsFeed - 18 Sep 2020
Orfadin(R) (nitisinone) receives positive opinion from CHMP for treatment of AKU
Orfadin(R) (nitisinone) receives positive opinion from CHMP for treatment of AKU
HSMN NewsFeed - 30 Sep 2019
Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
HSMN NewsFeed - 12 Jun 2019
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
HSMN NewsFeed - 22 Aug 2018
Sobi(TM) Appoints Anne Marie de Jonge Schuermans as Head of Technical Operations
Sobi(TM) Appoints Anne Marie de Jonge Schuermans as Head of Technical Operations
HSMN NewsFeed - 10 Nov 2017
Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development
Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development
HSMN NewsFeed - 25 Oct 2017
Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
HSMN NewsFeed - 6 Oct 2017
Norbert Oppitz Joins Sobi(TM) as New Senior Vice President, Specialty Care
Norbert Oppitz Joins Sobi(TM) as New Senior Vice President, Specialty Care
HSMN NewsFeed - 15 Aug 2017
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
HSMN NewsFeed - 30 Jun 2017
Xiapex(R) Gets Recommendation to be Made Available on National Health Service in England
Xiapex(R) Gets Recommendation to be Made Available on National Health Service in England
HSMN NewsFeed - 16 Jan 2017
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
HSMN NewsFeed - 11 Nov 2016
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
HSMN NewsFeed - 13 May 2016
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
HSMN NewsFeed - 5 May 2016
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership Appointments
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership Appointments
HSMN NewsFeed - 24 Nov 2015
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
HSMN NewsFeed - 20 Jul 2015
BioSpecifics Announces Approval of XIAFLEX(R) in Japan for the Treatment of Dupuytren's Contracture
BioSpecifics Announces Approval of XIAFLEX(R) in Japan for the Treatment of Dupuytren's Contracture
HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
HSMN NewsFeed - 13 Feb 2013
Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and Duricef(R); from PharmaSwiss
Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and Duricef(R); from PharmaSwiss
HSMN NewsFeed - 3 Feb 2011
Otonomy Adds Key Product and Industry Experience with Appointment of New Vice Presidents
Otonomy Adds Key Product and Industry Experience with Appointment of New Vice Presidents
HSMN NewsFeed - 27 Jan 2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab(R)
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab(R)
HSMN NewsFeed - 28 Dec 2010
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
HSMN NewsFeed - 23 Dec 2010
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
HSMN NewsFeed - 15 Sep 2008
Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen
Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen
Additional items found! 3

Members Archive contains
3 additional stories matching:
Biovitrum
(Password required)
Biovitrum
(Password required)